First-Line Treatment for Recurrent Respiratory Papillomatosis
Recurrent respiratory papillomatosis (RRP) is a condition that requires a defined, evidence-based first-line treatment approach. Selecting the correct initial regimen is critical to achieving disease control.
Treatment Approach
The established first-line regimen for recurrent respiratory papillomatosis is built around an interferon-based therapy. The specific dosing schedule, route, and duration of treatment are laid out in full in the structured protocol.
Complete regimen details are available through the link below.
References
DOI: 10.5005/jp-journals-10023-1008
The typical dose of interferon for children with RRP is 5 million units/m² body surface area administered by subcutaneous injection on a daily basis for 28 days, then 3 days per week for atleast a 6 month trial.
View source ↗